Atombeat and BioDuro Partner to Launch AI Platform for Faster Peptide Drug Discovery

Atombeat Inc., a leader in AI-driven drug discovery, and BioDuro, a global contract research, development, and manufacturing organization (CRDMO), have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug development.

The collaboration merges Atombeat’s advanced in silico modeling and AI-driven design tools with BioDuro’s expertise in discovery chemistry, biology, and drug metabolism/pharmacokinetics (DMPK). Together, the companies aim to streamline and speed up the discovery of high-quality cyclic peptides across a range of therapeutic areas — cutting both time and cost from traditional R&D workflows.

The new platform promises a fully integrated pipeline, from early molecular design to preclinical candidate selection. It leverages Atombeat’s proprietary technologies, including the Hermite software and RiDYMO platform, along with innovations like Reinforced Dynamics, Uni-Dock, Uni-FEP, and Uni-QSAR. These tools allow for the virtual screening of over one trillion peptide compounds—constructed from more than 1,000 natural and non-natural amino acids—before any laboratory testing begins.

“By filtering and prioritizing peptide candidates based on key traits like membrane permeability, our platform allows researchers to focus only on the most promising compounds,” said Dr. Dongdong Wang, co-founder of Atombeat. “This not only accelerates discovery but also reduces cost and risk.”

Following the virtual screening phase, BioDuro brings its high-throughput synthesis capabilities to bear, producing hundreds of peptides within a week, often ready for biological testing without the need for purification. Combined with rapid bioassays, this tight integration of AI and lab validation drastically compresses traditional R&D timelines.

“We’re excited to push the boundaries of peptide innovation with Atombeat,” said Dr. Armin Spura, CEO of BioDuro. “This partnership will deliver smarter, faster, and more comprehensive peptide solutions to our global clients.”

The companies aim to make the platform a go-to solution for pharmaceutical partners seeking to develop next-generation peptide therapies, particularly in areas with unmet medical needs.